Haworth, NJ, United States of America

Steven J Feinmark

USPTO Granted Patents = 2 

Average Co-Inventor Count = 2.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2012

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Steven J Feinmark: Innovator in Cancer Research

Introduction

Steven J Feinmark is a notable inventor based in Haworth, NJ (US). He has made significant contributions to the field of cancer research, particularly through his innovative patents. With a total of 2 patents, Feinmark's work focuses on understanding and treating cancer at a molecular level.

Latest Patents

Feinmark's latest patents include groundbreaking discoveries. The first patent, titled "Two pore channels as regulators of proliferation in cancer," relates to the increased expression of two pore K+ channel (2PK) genes in tumors and tumor cell lines, especially prostate tumor cells. This invention encompasses methods for disease diagnosis, drug screening, and the treatment of cancer. The second patent, "Method of treating a condition associated with phosphorylation of TASK-1," provides methods and compositions for treating conditions linked to the phosphorylation of TASK-1. This involves administering an agent effective in overcoming the phosphorylation-dependent loss of TASK-1 function, with a specific embodiment utilizing a TREK-1 agonist.

Career Highlights

Feinmark is affiliated with Columbia University, where he continues to advance his research and innovations. His work has garnered attention for its potential impact on cancer treatment and understanding.

Collaborations

Feinmark collaborates with Richard B Robinson, enhancing the research efforts in their respective fields. Their partnership exemplifies the importance of teamwork in scientific advancements.

Conclusion

Steven J Feinmark's contributions to cancer research through his patents highlight his role as an innovator in the field. His work not only advances scientific understanding but also holds promise for future therapeutic applications.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…